Pliant Therapeutics Inc (PLRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $42.97M
Last updated: Nov 17, 2026 at 4:06 PM ET
Pliant Therapeutics Inc (PLRX) Statistics
Pliant Therapeutics (PLRX) has a market cap of $42.97M and an enterprise value of $16.40M. Revenue fell 100.00% over the last 12 months from the 12 months before. It holds $26.57M more cash than debt, 61.83% of its market cap.
Total Valuation
Enterprise value is 61.83% below the market cap, as cash exceeds debt.
| Market Cap | $42.97M |
|---|---|
| Enterprise Value | $16.40M |
| Latest price (Nov 17, 2026) | $0.66 |
Key Dates
The next earnings report is expected on Mar 9, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 9, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 60.70% over 52 weeks and trades 31.25% below its 50-day average.
| Beta (1Y) | 0.90 |
|---|---|
| 52-Week Change | -60.70% |
| 1-Month Change | -26.54% |
| 3-Month Change | -43.57% |
| 6-Month Change | -42.59% |
| 5-Year Change | -94.61% |
| Total Return (1Y) | -60.70% |
| Total Return (3Y CAGR) | -64.02% |
| Total Return (5Y CAGR) | -46.96% |
| Max Drawdown (1Y) | -59.99% |
| Max Drawdown (3Y) | -96.63% |
| Sharpe Ratio (1Y) | -1.80 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $0.96 |
| 200-Day Average | $1.13 |
| 52-Week Range | $0.66 to $1.67 |
| RSI (14 Days) | 18.9 |
| Average Volume (20 Days) | 377.81K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 8.05x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 8.05x |
|---|---|
| Quick Ratio | 8.05x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| ROE (5Y Average) | -54.77% |
|---|---|
| ROA (5Y Average) | -45.99% |
Scores
PLRX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$365.00K |
| Operating Income | -$94.95M |
| Pretax Income | -$90.36M |
| Net Income | -$90.36M |
| Reported EPS (TTM) | -$1.42 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 74.54% of the $169.88M in total assets.
| Cash and Equivalents | $26.57M |
|---|---|
| Total Debt | $0 |
| Net Cash | $26.57M |
| Net Cash Per Share | $0.43 |
| Working Capital | $126.29M |
| Shareholder Equity | $126.63M |
| Book Value Per Share | $2.04 |
| Total Assets | $169.88M |
| Total Liabilities | $43.24M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$66.79M |
|---|---|
| FCF Per Share | -$1.08 |
| Depreciation and Amortization | $1.68M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -38.88% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -38.88% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PLRX
What is PLRX's market cap?
Pliant Therapeutics has a market cap of $42.97M. Its enterprise value, which adds debt and subtracts cash, is $16.40M.
How many shares of PLRX are outstanding?
Pliant Therapeutics has 61.94M shares outstanding. The count is up 0.88% from a year earlier.
Does PLRX pay a dividend?
No. Pliant Therapeutics does not pay a dividend.
How much debt does PLRX have?
Pliant Therapeutics has $0 of total debt and $26.57M of cash and equivalents, a net cash position of $26.57M.
PLRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors